ADSTILADRIN Early Utilization and Outcomes in the Real World Setting
(ABLE-41 Trial)
Trial Summary
What is the purpose of this trial?
Multi-center, prospective non-interventional study to collect data on the early use of Adstiladrin in the US and Israel. Data will be collected from patients and prescribing physicians in a real-world setting
Research Team
Global Clinical Compliance
Principal Investigator
Ferring Pharmaceuticals
Eligibility Criteria
Inclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Data Collection
Data collected from patients and prescribing physicians in a real-world setting
Follow-up
Participants are monitored for safety and effectiveness after treatment
Treatment Details
Find a Clinic Near You
Who Is Running the Clinical Trial?
Ferring Pharmaceuticals
Lead Sponsor
Pierre-Yves Berclaz
Ferring Pharmaceuticals
Chief Medical Officer since 2023
MD from the University of Lausanne, PhD in Molecular Biology from the Cincinnati College of Medicine
Jean-Frédéric Paulsen
Ferring Pharmaceuticals
Chief Executive Officer since 2023
Master’s degree in Finance from the London School of Economics and Political Science